AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
AstraZeneca AZN announced that the European Medicines Agency has accepted the Marketing Authorization Variation (MAV) for the label expansion of Forxiga (dapagliflozin). Forxiga, a selective SGLT-2 ...
Der Gemeinsame Bundesausschuss (GBA) spricht dem SGLT2-Hemmer Dapagliflozin (Forxiga® 5 mg) einen Zusatznutzen bei der Therapie von Erwachsenen mit Typ-1-Diabetes zu, teilt das Unternehmen AstraZeneca ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback